Stage Grouping

Stage grouping is the process of combining several individual cancer measurements — most often tumor size and location (T), lymph node involvement (N), and distant spread (M) — into a single overall stage, usually labeled I through IV. This single stage helps doctors describe how advanced the cancer is, predict prognosis, and choose treatment. For mesothelioma and lung cancer, stage groupings are defined by the American Joint Committee on Cancer (AJCC) and updated periodically.

Origin

The concept emerged in the 1940s–50s through the work of French surgeon Pierre Denoix, who developed the TNM system. The AJCC and the Union for International Cancer Control (UICC) later formalized stage groupings, with mesothelioma receiving its own dedicated staging system in the AJCC manual beginning in 1997.

Significance in Asbestos Context

For patients with mesothelioma or asbestos-related lung cancer, the stage group drives nearly every treatment decision, whether surgery is offered, whether chemotherapy or immunotherapy is given first, and whether clinical trials are appropriate. Stage I and II pleural mesothelioma may be candidates for aggressive surgery (such as pleurectomy/decortication or extrapleural pneumonectomy), while Stage III and IV are usually treated with systemic therapy. The stage recorded in your pathology and oncology notes will also appear in legal filings, because it directly affects life expectancy estimates and the value of damages. Be aware that staging can change after surgery or additional imaging (this is called pathological vs. clinical staging), and a more accurate stage may emerge weeks into treatment.

Example Sentence

After the PET scan and mediastinoscopy, the oncologist explained that the stage grouping had moved from clinical Stage II to pathological Stage III, which changed the treatment plan from surgery-first to chemotherapy-first.

Related Terms

TNM Staging, Clinical Staging, Pathological Staging, Prognosis, Mesothelioma, AJCC

Notes

• Ask your oncologist to write down both the TNM values (e.g., T2 N1 M0) and the overall stage group, and whether it is clinical (cTNM) or pathological (pTNM). These distinctions matter medically and legally.
• Request that the staging be done using the most recent AJCC edition (currently the 8th edition for mesothelioma), since older editions can produce different stage assignments for the same disease.
• Keep copies of every imaging report, operative note, and pathology report; if your stage is later revised, the documentation trail supports both medical decisions and any legal claim valuation.
• If you are considering a second opinion at a mesothelioma specialty center, bring the original imaging on disc. Re-staging by an experienced multidisciplinary team often changes the stage and the treatment plan.